SCHEMBL1938583

SCHEMBL1938583

C=CCOc1cc(OC)c(C=CC(=O)c2ccccc2)c(OCC=C)c1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 2/20 0.59
NPC1 O15118 3/20 0.53
MAPT P10636 3/20 0.53
RAB9A P51151 3/20 0.53
MAOA P21397 2/20 0.53
ALDH1A1 P00352 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
PTPN1 P18031 2/20 0.52
FLT3 P36888 1/20 0.51
CYP3A4 P08684 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
BCHE P06276 3/20 0.49
LMNA P02545 1/20 0.49
AURKA O14965 1/20 0.48
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1938581 1.00 ABCG2 (0.59) ABCG2NPC1MAPTRAB9AMAOA
SCHEMBL7184897 0.85 ABCG2 (0.45) ABCG2NPC1MAPTRAB9AMAOA
SCHEMBL7182842 0.85 ABCG2 (0.45) ABCG2NPC1MAPTRAB9AMAOA
SCHEMBL7184890 0.85 ABCG2 (0.45) ABCG2NPC1MAPTRAB9AMAOA
SCHEMBL4610668 0.82 ABCG2 (0.85) ABCG2NPC1MAPTRAB9AMAOA
SCHEMBL4610666 0.82 ABCG2 (0.85) ABCG2NPC1MAPTRAB9AMAOA
SCHEMBL7184568 0.82 ABCG2 (0.70) ABCG2MAPTMAOAALDH1A1SMN1; SMN2
SCHEMBL7184561 0.82 ABCG2 (0.70) ABCG2MAPTMAOAALDH1A1SMN1; SMN2
SCHEMBL1938567 0.79 MAPT (0.60) ABCG2NPC1MAPTRAB9AMAOA
SCHEMBL1938570 0.79 MAPT (0.60) ABCG2NPC1MAPTRAB9AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9061984-B2 Compounds related to chalcones and benzothienopyrimidines, their synthesis, and uses to treat diseases UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2015-06-23 US disclosed
US-20110190325-A1 COMPOUNDS, THEIR SYNTHESES, AND THIER USES THE JOHNS HOPKINS UNIVERSITY 2011-08-04 US disclosed
EP-2330906-A1 COMPOUNDS, THEIR SYNTHESES, AND THEIR USES University Of Louisville Research Foundation, Inc. (US) 2011-06-15 EP disclosed
WO-2010019861-A1 COMPOUNDS, THEIR SYNTHESES, AND THEIR USES UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) 2010-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190325-A1 COMPOUNDS, THEIR SYNTHESES, AND THIER USES TERT, TYMS, NISCH ABCG2 1032/4885NPC1 1044/4885MAPT 2194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.